LSIPR 50 2018: Richard Gonzalez
Name: Richard Gonzalez
Organisation: AbbVie
Position: CEO and Chairman
As CEO and chairman of the board at AbbVie, Richard Gonzalez has overseen a biopharmaceutical company that employs nearly 30,000 people and markets medicines in more than 175 countries since 2012.
Before AbbVie’s separation from Abbott, Gonzalez served as executive vice president of Abbott’s pharmaceutical products group, where he led the global pharmaceutical business, including commercial operations, research and development and manufacturing.
For 2018, AbbVie said it would take one single digit price increase and would continue to act responsibly with respect to drug pricing.
At the beginning of the year, AbbVie increased the price of Humira (adalimumab), the blockbuster rheumatoid arthritis/inflammatory disease treatment, by 9.7%.
Wells Fargo analyst David Maris reportedly said that this single price increase could add $1.2 billion to the US healthcare system’s drug costs this year.
